24.55
-2.62%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About STAAR Surgical
From its filings with the US Securities and Exchange Commission
STAAR Surgical is based in Monrovia, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker STAA. The SEC classifies its business as ophthalmic goods. In the fiscal year to 2 January 2026, it reported revenue of $239.4m and a net loss of $80.4m. At that date it held total assets of $451.7m and shareholders' equity of $344.2m.
We market and sell our ICLs for refractive surgery to treat myopia (nearsightedness) as our “EVO” family of lenses. We believe our EVO lenses are an “Evolution in Visual Freedom” designed to provide premium refractive outcomes while optimizing patient comfort. Our EVO family of lenses includes our EVO ICL, EVO+ ICL, and EVO Visian ICL. Our newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). We also market and sell an ICL lens to treat hyperopia (farsightedness), which we call our Visian ICL. We make our ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). Not all of our products are currently available in all markets where we sell ICLs today.
STAAR employs a commercialization strategy that strives for sustainable, profitable growth. Our growth strategy includes making our complete ICL product line available in our existing geographic markets and expanding into attractive markets where we do not sell our products today. In addition, we are focused on driving awareness of the ICL procedure and the clinical benefits of our ICLs, and providing surgeon training, support and education, particularly in our newer markets. Historically, the Company also manufactured and sold intraocular lenses (or “IOLs”) for use in surgery to treat cataracts.
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 8 Jul 1983
- Employees
- 957
- Website
- staar.com ↗
- Head office
- 1911 WALKER AVE, MONROVIA, CA, 91016
- Incorporated in
- DE
- Classification
- Ophthalmic Goods
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Elizabeth YeuNon-Executive Independent Chairman of the Board$250,013
- Mr. Warren FoustPresident, Chief Operating Officer$2.9m
- Mr. Stephen FarrellChief Executive Officer, Director, since 2016$295,013
- Ms. Deborah AndrewsChief Financial Officer$389,381
- Dr. Magda MichnaChief Development Officer$2.3m
- Mr. Nathaniel SisitskyChief Legal Officer and Corporate Secretary$2.1m
- Mr. Wei JiangDirector$286,256
- Mr. Arthur ButcherIndependent Director$275,801
- Mr. Louis SilvermanIndependent Director$52,445
- Ms. Lilian ZhouIndependent Director$246,964
- Mr. Brian MooreVice President - Investor Relations and Corporate Development, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 59
- Environment
- 67
- Social
- 99
- Governance
- 13
- Direct emissions (scope 1)
- 16.5 t
- Energy emissions (scope 2)
- 1,338 t
- Women in the workforce
- 47%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- STAAR Surgical Co has several strengths that contribute to its success. One of the key strengths is its strong portfolio of innovative surgical products. The company's products are known for their high quality and effectiveness, providing significant benefits to patients and healthcare professionals.
- Additionally, STAAR Surgical Co has a solid reputation and brand recognition in the medical industry. This recognition has helped the company gain market share and build strong relationships with healthcare providers and distributors.
- Furthermore, the company has a skilled and experienced leadership team that guides its strategic decisions and drives growth. Their expertise in the industry has allowed the company to navigate challenges and seize opportunities effectively.
Weaknesses
- Despite its strengths, STAAR Surgical Co also faces a few weaknesses. One of the main weaknesses is its limited geographical presence. The company operates primarily in the United States and has limited market penetration in other regions. This hinders its potential for global growth and exposes it to market-specific risks.
- Another weakness is the company's heavy reliance on third-party suppliers for critical components of its products. Any disruption or issues with these suppliers could impact the company's production and supply chain, leading to potential delays or shortages.
- Lastly, STAAR Surgical Co faces intense competition from established players in the ophthalmic surgical products industry. This competitive environment puts pressure on the company to consistently innovate and differentiate itself to maintain market share.
Opportunities
- STAAR Surgical Co has several opportunities that it can capitalize on for further growth and success. Firstly, the rising global prevalence of eye-related conditions and diseases presents a significant opportunity for the company to expand its market reach.
- Moreover, advancements in technology and surgical techniques create opportunities for the development of new and improved products. STAAR Surgical Co can invest in research and development to introduce cutting-edge solutions that address the evolving needs of healthcare professionals and patients.
- Additionally, expanding its distribution network and entering untapped international markets can help the company diversify its revenue streams and reduce its reliance on the US market.
Threats
- STAAR Surgical Co faces several threats that could impact its performance. One significant threat is the regulatory environment. Changes in regulations, compliance requirements, or the introduction of new standards can increase the company's costs and pose challenges to its operations.
- Another threat is the potential for intellectual property infringement. Competitors or other entities may try to replicate or imitate STAAR Surgical Co's products, undermining its market position and revenue streams.
- Lastly, economic downturns and fluctuations in healthcare spending can negatively impact the demand for surgical products and services, affecting STAAR Surgical Co's financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.